BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) updated its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 4.900-5.100 for the period, compared to the consensus EPS estimate of 4.800. The company issued revenue guidance of $3.9 billion-$3.9 billion, compared to the consensus revenue estimate of $3.9 billion.
Analyst Ratings Changes
Several equities analysts have recently commented on BMRN shares. Wall Street Zen lowered BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Saturday, June 6th. Morgan Stanley dropped their target price on BioMarin Pharmaceutical from $120.00 to $119.00 and set an “overweight” rating for the company in a research report on Tuesday, May 5th. Weiss Ratings raised BioMarin Pharmaceutical from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, June 26th. The Goldman Sachs Group started coverage on shares of BioMarin Pharmaceutical in a research report on Monday, May 11th. They set a “neutral” rating and a $69.00 price target on the stock. Finally, Citigroup lifted their price target on shares of BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, BioMarin Pharmaceutical has an average rating of “Moderate Buy” and a consensus target price of $87.09.
BioMarin Pharmaceutical Trading Up 2.6%
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) last released its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.25. The company had revenue of $989.71 million during the quarter, compared to analyst estimates of $932.03 million. BioMarin Pharmaceutical had a return on equity of 6.50% and a net margin of 8.29%.BioMarin Pharmaceutical’s revenue for the quarter was up 20.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.44 EPS. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. As a group, equities analysts anticipate that BioMarin Pharmaceutical will post 4.22 EPS for the current fiscal year.
BioMarin Pharmaceutical News Roundup
Here are the key news stories impacting BioMarin Pharmaceutical this week:
- Positive Sentiment: Quarterly earnings and revenue beat estimates. BioMarin reported quarterly EPS of $1.20, above consensus estimates ranging from $0.94 to $0.96. Revenue rose 20% year over year to approximately $990 million, exceeding analysts’ expectations of about $932 million. BioMarin Pharmaceutical Surpasses Q2 Earnings and Revenue Estimates
- Positive Sentiment: Full-year EPS guidance was raised above expectations. Management now expects fiscal 2026 EPS of $4.90-$5.10, compared with the consensus estimate of $4.80. The company also cited stronger growth expectations for revenue and VOXZOGO, supporting the improved outlook. BioMarin Reports Second Quarter 2026 Financial and Operating Results
- Positive Sentiment: New products could strengthen longer-term growth. BioMarin said the addition of GALAFOLD and POMBILITI plus OPFOLDA, together with expected cost synergies, should accelerate revenue growth, expand operating margins, increase cash flow and be accretive to non-GAAP EPS through the mid-2030s. BioMarin Reports Second Quarter 2026 Financial and Operating Results
- Neutral Sentiment: Revenue guidance was maintained broadly in line with consensus. Full-year revenue guidance of approximately $3.9 billion matched analysts’ expectations, so the principal upside came from the stronger-than-expected earnings outlook rather than a revenue forecast increase.
- Negative Sentiment: Reported EPS declined from the prior-year period. Quarterly EPS fell from $1.44 to $1.20, although the result still surpassed analyst estimates and revenue growth remained strong. BioMarin Q2 Earnings Snapshot
Institutional Trading of BioMarin Pharmaceutical
A number of institutional investors have recently made changes to their positions in the stock. Sivia Capital Partners LLC raised its position in BioMarin Pharmaceutical by 33.0% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,439 shares of the biotechnology company’s stock valued at $244,000 after purchasing an additional 1,102 shares during the last quarter. FORA Capital LLC bought a new stake in shares of BioMarin Pharmaceutical in the 4th quarter worth approximately $224,000. Prelude Capital Management LLC purchased a new position in shares of BioMarin Pharmaceutical during the third quarter valued at approximately $288,000. NorthRock Partners LLC increased its stake in shares of BioMarin Pharmaceutical by 11.8% during the third quarter. NorthRock Partners LLC now owns 5,420 shares of the biotechnology company’s stock valued at $294,000 after buying an additional 574 shares during the period. Finally, Osaic Holdings Inc. raised its holdings in shares of BioMarin Pharmaceutical by 54.8% during the second quarter. Osaic Holdings Inc. now owns 5,064 shares of the biotechnology company’s stock valued at $283,000 after acquiring an additional 1,793 shares in the last quarter. Hedge funds and other institutional investors own 98.71% of the company’s stock.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.
The company’s commercial portfolio includes several approved therapies targeting inherited disorders.
Read More
- Five stocks we like better than BioMarin Pharmaceutical
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
